Clinical and Translational Medicine (Sep 2021)
A CRISPR/dCasX‐mediated transcriptional programming system for inhibiting the progression of bladder cancer cells by repressing c‐MYC or activating TP53
Abstract
No abstracts available.
Clinical and Translational Medicine (Sep 2021)